Review Article
Volume 17 Issue 2 - 2021
Severity Assessment and Management of Chronic Obstructive Pulmonary Disease
Rasha Khaled Sendy1*, Qusai Munir Dahlawi2, Ziyad Saud Rasheed Al Mjlad3, Muhammed Ibrahim4, Abdulrahman Saleh Alaql5, Sultan Anwar Aljudaibi6, Malik Ahmad Ibrahim Alqubaie7, Amjad Fawaz Alshammari8, Mayssan Hussein Almalki9, Amjad Meshal Allahyani9, Esam Mousa Aqeeli10, Abdullah Naif Albugami11 and Abdulrahman Omar Mansy12
1King Fahad General Hospital, Jeddah, Saudi Arabia
2Alnoor Specialist Hospital, Makkah, Saudi Arabia
3King Saud Medcail City, Riyadh, Saudi Arabia
4Al Abeer International Medical Center, Saudi Arabia
5Aladel Primary Health Care, Jeddah, Saudi Arabia
6Ibn Sina National College, Jeddah, Saudi Arabia
7Assir Hospital, Assir, Saudi Arabia
8King Fahad Medical City, Riyadh, Saudi Arabia
9King Abdullah Medical Complex, Jeddah, Saudi Arabia
10Khulais General Hospital, Khulais, Saudi Arabia
11Security Forces Hospital, Riyadh, Saudi Arabia
12Taif University, Taif, Saudi Arabia
*Corresponding Author: Rasha Khaled Sendy, Medical Registrar, King Fahad General Hospital, Jeddah, Saudi Arabia.
Received: January 16, 2021; Published: January 20, 2021




Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is classified as a fatal disease, with a very high rate of morbidity and mortality. It is associated with acute exacerbations, so the patients are usually undergoing frequent hospitalizations and chronic therapy. Fortunately, the appropriate controlling of the disease has positive effects such as reducing the frequency, exacerbations, and improving the health overall.

Aim of the Work: In this review, we will outline the principles of assessment and management of patients with various severity of chronic obstructive pulmonary disease. In addition, we discussed some aspects related to COPD management during Covid-19 pandemic.

Methods: A non-systematic, thorough search of the biomedical literature between 2010 and 2020 was conducted. All observational and interventional studies addressing chronic obstructive lung disease were screened.

Conclusion: Avoidance of triggers exposures, vaccines used for respiratory infections, drugs-using learning, exacerbation identification and management are all general measures considered correct for all patients with COPD. For patients who are suffering from intermittent increasing in dyspnea, the drug of choice in this case is short acting bronchodilators. The recommendation for patients who are at low risks of exacerbation and more symptomatic is a regular use of a long-acting bronchodilator with short-acting bronchodilator, prescribed as-needed for intermittent increases in dyspnea. In patients with mMRC ≥ 2, CAT score ≥ 10 and a ≥ 2 exacerbations per year with one or more hospitalization, the best initial treatment in this case is long-acting anticholinergic agent. Recommendations do not advise the patients with COPD to stop any medications they are regularly taking, including corticosteroid. If the patient admitted to the hospital due to COVID-19, using of nebulized medications should be avoided to reduce infectious spreading.

Keywords: COPD; Assessment; Pattern; Control; Management

References

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). “Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease” (2020).
  2. Guan WJ., et al. “Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis”. European Respiratory Journal (2020): 55.
  3. Buist AS., et al. “International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study”. Lancet 370 (2007): 741.
  4. Rennard SI and Vestbo J. “COPD: the dangerous underestimate of 15%”. Lancet 367 (2006): 1216.
  5. National Jewish Health Video Library. “Devices to inhale medication (Asthma inhalers, COPD inhalers)” (2018).
  6. Make B. “Collaborative self-management strategies for patients with respiratory disease”. Respiratory Care 39 (1994): 566.
  7. McCarthy B., et al. “Pulmonary rehabilitation for chronic obstructive pulmonary disease”. Cochrane Database of Systematic Reviews (2015): CD003793.
  8. Malinovschi A., et al. “Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients”. Respiratory Research 15 (2014): 131.
  9. Rafiq R., et al. “Prevention of exacerbations in patients with COPD and vitamin D deficiency through vitamin D supplementation (PRECOVID): a study protocol”. BMC Pulmonary Medicine 15 (2015): 106.
  10. Hanania NA., et al. “Bronchodilator reversibility in COPD”. Chest 140 (2011): 1055.
  11. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group”. Chest 105 (1994): 1411.
  12. Ram FS and Sestini P. “Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis”. Thorax 58 (2003): 580.
  13. Cook D., et al. “Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease”. American Journal of Respiratory and Critical Care Medicine 163 (2001): 85.
  14. Wilchesky M., et al. “Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort”. Chest 142 (2012): 305.
  15. Wadbo M., et al. “Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study”. European Respiratory Journal 20 (2002): 1138.
  16. No Zhou Y., et al. “Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease”. The New England Journal of Medicine 377 (2017): 923.
  17. Dorinsky PM., et al. “The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD”. Chest 115 (1999): 966.
  18. Donohue JF., et al. “A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol”. Chest 122 (2002): 47.
  19. Chong J., et al. “Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease”. Cochrane Database of Systematic Reviews (2012): CD009157.
  20. Tashkin DP., et al. “A 4-year trial of tiotropium in chronic obstructive pulmonary disease”. The New England Journal of Medicine 359 (2008): 1543.
  21. Gershon A., et al. “Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease”. JAMA Internal Medicine 173 (2013): 1175.
  22. Donohue JF., et al. “Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium”. American Journal of Respiratory and Critical Care Medicine 182 (2010): 155.
  23. Calverley PM., et al. “Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease”. The New England Journal of Medicine 356 (2007): 775.
  24. Kew KM., et al. “Long-acting beta2-agonists for chronic obstructive pulmonary disease”. Cochrane Database of Systematic Reviews (2013): CD010177.
  25. Donohue JF., et al. “One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD”. Chest 146 (2014): 1531.
  26. Chowdhury BA., et al. “The risks and benefits of indacaterol--the FDA’s review”. The New England Journal of Medicine 365 (2011): 2247.
  27. Joos GF., et al. “A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive (2015).
  28. Koch A., et al. “Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studi (2014).
  29. Wise RA., et al. “Tiotropium Respimat inhaler and the risk of death in COPD”. The New England Journal of Medicine 369 (2013): 1491.
  30. Vogelmeier C., et al. “Tiotropium versus salmeterol for the prevention of exacerbations of COPD”. The New England Journal of Medicine 364 (2011): 1093.
  31. Frampton JE. “QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease”. Drugs 74 (2014): 465.
  32. Martinez FJ., et al. “Pooled Analyses from PINNACLE-1 and -2: The Novel LAMA/LABA Co-Suspension Technology Glycopyrrolate/Formoterol Fixed-Dose Combination Delivered by MDI Shows Improvement Versus Monocomponents in Patient”.
  33. Sharafkhaneh A., et al. “Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study”. Respiratory Medicine 106 (2012): 257.
Citation: Rasha Khaled Sendy., et al. “Severity Assessment and Management of Chronic Obstructive Pulmonary Disease”. EC Microbiology 17.2 (2021): 187-195.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before April 26, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk